Standard endocrine therapy

Phase 3Small molecule

SShanghai Changzheng Hospital

Standard endocrine therapy is one of 85 small molecule programs targeting Breast Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CarcinomaActive, not recruiting

Prostate CancerNot yet recruiting

Breast CarcinomaPhase 3

Active, not recruiting

Prostate CancerPhase 1

Not yet recruiting

Competition

Competitive Landscape

348 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 3

26 2

Yervoy

Bristol-Myers Squibb

Phase 3

20 3

Lupron

EEastern Cooperative Oncology Group

Phase 3

53 4

Tecentriq

Roche

Phase 3

8 5

Xaluritamig

Amgen

Phase 3

4 6

Provenge

PProstate Oncology Specialists, Inc.

Phase 3

21 7

Fluciclovine

UUniversity of Utah

Phase 3

3 8

AAA817

Novartis

Phase 3

1 9

Standard endocrine therapy

SShanghai Changzheng Hospital

Phase 3

1 10

Trexall

Jazz Pharmaceuticals

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Not yet recruiting

Prostate Cancer

NCT07389174

Q1 2029

Phase 3Active, not recruiting

Breast Carcinoma

NCT03820830

Clinical

Trials by Indication[1]

Prostate Cancer1 trial

Safety and Efficacy Evaluation of LC-K76 in Patients With Metastatic Hormone-Sensitive Prostate Cancer

Not yet recruiting·SShanghai Changzheng Hospital·Phase 1·NCT07389174·40 enrolled

Breast Carcinoma1 trial

A Phase III Open-label, Multicenter, Randomized Trial of Adjuvant Palbociclib in Combination With Endocrine Therapy Versus Endocrine Therapy Alone for Patients With Hormone Receptor Positive / HER2-negative Resected Isolated Locoregional Recurrence of Breast Cancer

Active, not recruiting·EETOP IBCSG Partners Foundation·Phase 3·NCT03820830·405 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Standard endocrine therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Standard endocrine therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Standard endocrine therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Changzheng Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SShanghai Changzheng Hospital

Standard endocrine therapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q1 2029

Trials by Indication[1]

Prostate Cancer1 trial

Breast Carcinoma1 trial

References

Drug Info

Quick Facts

Related News